3-methyl-2,3-dihydro-1H-quinolin-4-one | 30448-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-methyl-2,3-dihydro-1H-quinolin-4-one
• 英文别名: 3-Methyl-2,3-dihydro-1H-chinolin-4-on；2,3-Dihydro-3-methyl-4(1H)-quinolinone；3-methyl-2,3-dihydro-1H-quinolin-4-one
• CAS: 30448-38-5
• 化学式: C₁₀H₁₁NO
• 分子量: 161.203
• InChiKey: XDIJRKJCKGZOHH-UHFFFAOYSA-N

物化性质

• 沸点：
  301.4±22.0 °C(Predicted)
• 密度：
  1.083±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-Allyl-N-(2-cyano-phenyl)-4-methyl-benzenesulfonamide 在 正丁基锂 、 Co₂ZrCl₂ 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 14.0h， 以30%的产率得到3-methyl-1-tosyl-2,3-dihydroquinolin-4(1H)-one
  参考文献：
  名称：

  锆促进亚硝酸盐与烯烃的还原偶联形成环

  摘要：

  在由（C 5 H 5）2 ZrCl 2和BuLi制得的茂茂锆存在下，亚硝酸盐与烯烃单元的分子内还原偶联反应得到环状酮。由2-氰基-N-烯丙基苯胺衍生物制备的中间体金属环烷具有很高的反应活性，并通过亲电试剂和其他试剂处理可提供各种喹啉衍生物。

  DOI：

  10.1039/c39900001222

文献信息

• METHODS FOR TREATING SCHIZOPHRENIA
  申请人：Lichter Jay

  公开号：US20120184547A1

  公开（公告）日：2012-07-19

  Provided herein are PAK inhibitors. Also provided herein are compositions and methods for treating an individual suffering from schizophrenia.

  提供PAK抑制剂。此外，还提供了用于治疗患有精神分裂症的个体的组合物和方法。
• METHODS FOR TREATING NEUROLOGICAL CONDITIONS
  申请人：Lichter Jay

  公开号：US20130225575A1

  公开（公告）日：2013-08-29

  Provided herein are PAK inhibitors. Also provided herein are compositions and methods for treating an individual suffering from certain neurological conditions.

  本文提供了PAK抑制剂。同时提供了用于治疗患有某些神经疾病的个体的组合物和方法。
• Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2133078A1

  公开（公告）日：2009-12-16

  The present invention relates to cholinesterase inhibitors such a donepezil for the treatment of cognitive impairments and/or dementia associated with or caused by brain tumors.

  本发明涉及多奈哌齐等胆碱酯酶抑制剂，用于治疗与脑肿瘤相关或由脑肿瘤引起的认知障碍和/或痴呆症。
• MORI, MIWAKO;UESAKA, NORIAKI;SHIBASAKI, MASAKATSU, J. CHEM. SOC. CHEM. COMMUN.,(1990) N8, C. 1222-1224
  作者：MORI, MIWAKO、UESAKA, NORIAKI、SHIBASAKI, MASAKATSU

  DOI：——

  日期：——
• METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS
  申请人：Ieni John

  公开号：US20090042940A1

  公开（公告）日：2009-02-12

  The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine.